The Insulin like growth factor 2 (IGF2) gene is expressed in several types of tumors in humans and mice and has been implicated as an important growth factor in tumor progression. IGF2 expression in the TGFa transgenic mice was analysed in liver and tumors from animals which also contained one or two functional IGF2 alleles. In a two by two mating experiment using transgenic mice containing either a TGFa transgene or a IGF2 gene knockout, we have investigated whether IGF2 imprinting is reversed during hepatocarcinogenesis and the consequences of IGF2 expression for tumor growth. We observed that: (1) 100% of the hepatocellular carcinomas expressed IGF2 (2) the normally imprinted maternal allele is active in the tumors in which the paternal allele is knocked out and (3) all three of the murine IGF2 promoters upstream of the reactivated maternal alleles are transcriptionally active in tumors. We also observed that the total tumor burden of animals with two wild type IGF-2 alleles (paternal and maternal) was the same as the tumor burden in animals which contained only a single reactivated maternal allele. The 100% incidence of reactivation of the imprinted maternal allele suggests that IGF2 expression is selected during murine hepatocarcinogenesis and can substitute for the paternal allele when it is inactivated.
Introduction
Insulin like growth factor 2 (IGF2) is a growth factor possessing mitogenic, morphogenic and metabolic properties (Pimentel, 1994; Kiess et al., 1994; Rogler et al., 1994; Rossetti et al., 1996) . It is believed to function primarily as a prenatal growth factor but it has also been implicated in myoblast dierentiation (DeChiara et al., 1990 (DeChiara et al., , 1991 Florini et al., 1993) , neuronal outgrowth (Lauterio, 1992) and bone reformation (Shinar et al., 1993) . The gene is regulated at transcriptional and translational levels and is a member of a growing family of genes regulated by genomic imprinting (DeChiara, et al., 1990 (DeChiara, et al., , 1991 . Genome imprinting is a process whereby the expression of a particular allele is dependent upon the sex of the parent transmitting the gene. This eectively renders the gene hemizygous since only one parent will transmit an active copy. The active copy of the IGF-2 gene is transmitted from the male.
IGF2 expression begins as early as the blastocyst stage (Ohlsson et al., 1989) and continues primarily in the liver, muscles, lungs, ossifying bone and developing CNS during development. In the adult mouse IGF2 expression ceases in most of the tissues with the exception of the leptomeninges and choroid plexus of the brain which, express both paternal and maternal alleles (DeChiara et al., 1991) . Humans exhibit similar patterns of expression with one major exception, adults continue to express IGF2 in the liver, and the maternal allele is expressed through the use of an alternate, nonimprinted, promoter (Vu and Homan, 1994; DePagter-Holthuizen et al., 1988) .
Overexpression of IGF2 has been observed in tumors of the lung (Suzuki et al., 1994) , ovary (Yun et al., 1996) , breast (Singer et al., 1995) and liver (Lee et al., 1992; Fu et al., 1988; Yang and Rogler 1991; Schirmacher et al., 1992; Cariani et al., 1988) . It has been proposed that IGF2 could be a critical growth factor, aecting the total number of tumors formed and their rate of growth (Fu et al., 1988; Yang et al., 1996; Schirmacher et al., 1992; Christofori et al., 1994) . Christofori et al. (1995) observed that endogenous IGF2 gene expression was activated in precancerous lesions and islet cell carcinomas of the pancreas in transgenic mice which express SV40 large T-antigen under regulation of the rat insulin promoter. To test the hypothesis that IGF2 had a functional role in the development of pancreatic tumors, SV40 T-antigen transgenic mice were crossed with transgenic mice containing an IGF2 gene knockout (De Chiara et al., 1990; Christofori et al., 1995) . When tumors formed in the animals, a direct correlation was observed between the number of functional IGF2 genes (1 or 2) and the volume of tumors formed in the pancreas. There was a ®vefold higher apoptotic index in tumors which lacked IGF2, suggesting that IGF2 plays a role in suppressing apoptosis.
A similar role for IGF2 has been proposed for hepatocarcinogenesis . During hepatic oncogenesis in hepatitis B virus carriers, IGF2 gene expression is reactivated in precancerous lesions (Fu et al., 1988; Yang and Rogler, 1991) . In the woodchuck hepatitis virus (WHV) animal model IGF2 is highly overexpressed in a coordinate manner with Nmyc in precancerous lesions (Yang et al., 1993) . In addition, as tumor progression occurs in the WHV model, higher levels of expression of both N-myc and IGF2 are selected (Yang et al., 1993) . A selection for higher IGF2 in sub-foci of precancerous lesions and in tumors was also a characteristic of the pancreatic system (Christofori et al., 1994) . Finally, in liver cell cultures, N-myc overexpression can induce apoptosis and IGF2 blocks the apoptosis Ueda and Ganem, 1996) . SV40 large T Ag promotes oncogenesis by inactivating both the retinoblastoma (Rb) and P53 tumor suppressor genes (Ludlow et al., 1989; Greenblatt et al., 1994) . In liver, Rb and P53 inactivation have not been clearly implicated in the initiation events and sporadically play a role in later events of tumor progression (Greenblatt et al., 1994) . Therefore, we decided to investigate whether IGF2 would have a similar promoter role in a slow developing tumorigenesis model driven by a tumor growth factor alpha transgenic (TGFa). TGFa is a gene which is normally reactivated during hepatocarcinogenesis (Steinmetz and Klaunig, 1996; Collier et al., 1993; Kaufmann et al., 1992) . HCCs develop in TGFa transgene mice with a 12 ± 18 month latency and were previously shown to re-express IGF2 as well as c-myc (Takagi et al., 1992) . We wanted to investigate whether imprinting, which normally blocks IGF2 expression from the maternal allele in liver, would be relaxed during cancer initiation or progression. To do this we crossed the TGFa transgenic mice with a transgenic line possessing a hemizygous knockout for the IGF2 gene. Finally, since the murine IGF2 gene has three promoters, we investigated whether all three promoters were activated in tumors.
Results
The murine IGF2 gene is reactivated in slow developing hepatocellular carcinomas, and all three 5' promoters are utilized During development, the murine IGF2 gene produces multiple transcripts through the use of three dierent IGF2 promoters. The transcripts have dierent 5' starting exons (Rotwein and Hall, 1990) . We developed a reverse transcription PCR strategy to detect IGF2 transcripts speci®c for each of the IGF2 starting exons (Figure 1a ). Total RNA from tumor and normal tissue, from the same lobe of the liver, was reverse transcribed and aliquots of the resulting cDNA were subjected to 25 cycles of PCR. We used speci®c 5' oligonucleotides from the dierent untranslated transcriptional start sites and, 3' oligonucleotides located within the coding portion of the gene to eliminate false positives due to DNA contamination. Under these conditions we were able to detect PCR products representing all three start sites in samples from fetal mouse liver ( Figure 1b The RT ± PCR assay was used to determine whether all the IGF2 promoters were expressed in HCC's which arose in the TGFa transgenic mice in our study (Group 3, Table 1 ). Transcripts from all three IGF2 promoters were detected in 20/20 HCCs developing in TGFa transgenic mice which carried two wild type IGF2 alleles (Group 3 animals, example in Figure 1b , lane 2). This study recon®rmed that hepatocellular carcinomas arising in TGFa mice re-express endogenous IGF2 genes and demonstrated that all three transcriptional start sites are utilized. The re-expression of IGF2 was restricted to tumor tissue and was not seen in normal tissue taken from peritumor liver (Figure 1b , lane 1).
The maternal IGF2 allele is reexpressed in TGFa induced hepatocellular carcinomas
We produced animals in which the paternal IGF2 gene was knocked out by crossing hemizygous TGFa females with males which were heterozygous for the IGF2 gene knockout (DeChiara et al., 1990) . The ospring of this experiment were organized into four test groups (Table 1) . Group one animals contained two wild type IGF2 alleles and no TGFa transgene. One out of 25 animals in this group developed a liver tumor at 18 months old and it was classi®ed as an adenoma. This group served as a control for the mixed genetic background of the animals in our study and the low incidence of tumors in Group 1 animals led us to conclude that the mixed genetic background did not predispose the animals to hepatocarcinogenesis up to the age of 18 months.
Group two animals contained a paternally inherited IGF2 knockout allele, but no TGFa transgene. All 11 animals in this group were dwarves indicating the lack of IGF2 expression during embryonic development. The livers of these animals were all normal. Histological examination of random sections of 18 month old animals did not reveal the presence of any precancerous lesions or HCC's.
The third and fourth groups consisted of animals which contained a single TGFa transgene (driving tumor initiation) and either two IGF2 alleles (Group 3, n=9) or a paternally inherited IGF2 knockout allele plus a wild type maternal allele, (Group 4, n=8). All of the TGFa mice in groups 3 and 4 developed hepatocellular carcinomas by 18 months of age. IGF2 gene expression in tumors and surrounding liver was assayed by RT ± PCR and we detected IGF2 transcripts in 100% of the tumors from both groups (Table 1) . Our RT ± PCR assay was designed to detect only WT IGF2 transcripts. Transcripts deriving from the paternally derived mutant allele would not be detected (due to the presence of the Neomycin gene in the ®rst coding exon of the knocked out allele). Therefore, the presence of IGF2 transcripts in tumors from the group 4 animals is a result of the reactivation of the maternal allele in all of the tumors observed in this group of animals ( Analysis of promoter usage of the maternal alleles that were reactivated in HCCs revealed that 93% of the reactivated maternal alleles expressed all three promoters, 5% of the tumors did not utilize promoter 1 and 7% did not utilize promoter 2. Therefore, reexpression of all three imprinted IGF2 promoters occurs predominantly but is not universal. All three of the alternatively spliced mRNA's contained the entire IGF2 ORF and should be functional for translation RT ± PCR was performed using the coding sequence primers reported by Christofori et al. (1995) . This assay also detected speci®c IGF2 mRNA transcripts in tumors with one (Group 4) or two (Group 3) functional IGF2 alleles (Figure 3a) . Since some IGF2 mRNAs may not be translated, we tested for translation of IGF2 in group 3 and 4 HCCs. Western blot analysis revealed a 7.5 kd fully processed IGF2 polypeptide in the tumor tissues from group 3 and 4 animals ( Figure  3b ). These data demonstrated that the maternal allele produced mRNAs which were translated and processed to mature 7.5 Kd IGF2 polypeptides. Furthermore, the IGF2 polypeptides accumulated in the liver.
Analysis of the total tumor burden of group 3 versus 4 mice revealed that the number of tumors and the overall tumor burden (in grams) per mouse was not signi®cantly dierent (Table 1) . These data support the conclusion that IGF2 derived from the maternal allele in group 4 mice was sucient to produce the same eect as the IGF2 that was normally produced from wild type alleles in Group 3 mice.
Discussion
Insulin like growth factor 2 (IGF2) is a growth factor possessing both mitogenic and metabolic properties (Pimentel et al., 1994) . In mice, this gene is inactivated Re-expression of IGF2 in TGFa induced hepatocellular carcinomas produces transcripts utilizing all three IGF2 promoters. Reverse transcription PCR was used to detect whether IGF2 transcripts were present in tumors or normal tissues from the same animal. (a) Schematic diagram illustrating the Exon 1, 2 and 3 speci®c Oligos which were used to determine whether the three IGF2 promoters were used during the reactivation of endogenous IGF2 genes. Primers from either exon 4 or 6 were used for the downstream sequences as illustrated. (b) Ethidium bromide stained agarose gel of RT ± PCR products produced using the exon speci®c primers demonstrate that IGF2 is only expressed in tumor tissue and all three start sites are expressed. Lane 1 Absence of RT ± PCR products from normal liver or lane 2 RT ± PCR products from tumor tissue of a TGFa transgenic mouse liver (Table 1 , group III). Lane 3 RT ± PCR products from control livers of an adult (Table 1 , Group 1) or Lane 4 RT ± PCR from a 3 day old perinatal C57B16 animal. Exon 1, 2, 3, levels refer to products as illustrated in (a) BMI is the positive control in all tissues except the choroid plexus and leptomeninges of the brain within the ®rst few weeks after birth (Pintar et al., 1991; Pimentel, 1994) . Our study used a metallothionine promoter driven TGFa transgene which is expressed in the liver, resulting in hepatocarcinogenesis with a latency of approximately 12 ± 18 months. IGF2 is normally expressed from the paternal allele, and therefore in order to knock out the normally expressed gene we used a male partner to transmit the IGF2 null allele to the TGFa mice. Our study was designed to determine, (1) whether or not all three of the IGF2 promoters were utilized when IGF2 was reactivated in HCCs and (2) whether the same three promoters of the imprinted maternal IGF2 allele could be reactivated in mice when the paternal allele was knocked out and (3) whether production of IGF2 from the maternal IGF2 allele could substitute for IGF2 normally produced from the paternal allele. Analysis of IGF2 expression in HCC's of TGFa mice containing two wild type IGF2 alleles revealed expression in 100% of the HCCs demonstrating that reactivation of IGF2 is a very common event in TGFa mice. This was higher than the 75% observed earlier for the same line of transgenic mice (Takagi et al., 1992) and probably represents the increased sensitivity of the RT ± PCR assay used to detect IGF2 expression. A Western blot demonstrated that the IGF2 mRNAs were translated into protein which was fully processed to mature 7.5 kd IGF2 polypeptides.
The murine IGF2 gene possesses three promoters which produce three IGF2 mRNAs with dierent 5' starting exons. To determine whether all three murine IGF2 promoters could be reactivated we developed a RT ± PCR strategy that distinguished between transcripts from each of the murine IGF2 promoters. Using the RT ± PCR assay we detected transcripts from all three predicted transcriptional start sites showing that all of the murine promoters were reactivated in HCCs. Our oligos spanned dierent exons and RNA samples subjected to PCR without prior reverse transcription did not produce a product (data not shown) demonstrating that the PT ± PCR products were not produced from a contaminating genomic DNA template. We chose to use 24 PCR cycles Figure 2 Expression of the material IGF2 allele in TGFa induced HCCs. Ethidium bromide stained agarose gel of the RT ± PCR products from the cross between animals with the TGFa transgene and animals with an IGF2 knockout using the exon speci®c primers as illustrated in Figure 1a . Lane 1 products of peritumor liver or Lane 2 tumor tissue from an animal possessing the TGFa transgene and an inactive paternal IGF2 gene (Table 1 , group IV). Lane 3 Products from an animal with only the paternally inactive IGF2 gene no TGFa gene or tumors (Table 1 , group II). Lane 4 products from the livers of animals with two IGF2 genes and no TGFa transgene (Table 1 , group I). Lane 5 products from control 3 day old C57B16 mouse (instead of 30 or 40) to reduce the possibility of detecting low levels of random transcripts. Using this protocol, we did not detect IGF2 expression in normal liver tissues. Studies have suggested that 5' untranslated regions of varying lengths can eect translation eciency (De Moor et al., 1994 , 1995 Ayoubi et al., 1996; Wakiyama et al., 1992) . Our Western blot shows the presence of IGF2 protein in the tumors of TGFa animals containing a paternal knockout, demonstrating that the IGF2 mRNA from the maternally reactivated allele was translated into protein. Our data suggest that the reactivation of the single maternal IGF2 gene in group 4 animals was sufficient to maintain a total tumor burden equivalent to that of group 3 animals which contained two wild type IGF2 alleles.
The mechanism of IGF2 action in the liver is controversial. The mitogenic action of IGF2 is generally thought to function through cross reaction with IGFI receptors and IGFI receptors are not detectable in liver (Rotwein and Hall, 1990) . However, IGFI receptors have been detected in malignantly transformed liver cells which overexpress IGF2 (Zhang et al., 1997) . The liver is also a rich source of insulin receptors and the insulin signaling molecule, Insulin Receptor Substrate-1, (IRS-1) (Furusaka et al., 1994; Tanaka and Wands, 1996a,b; Nishiyama and Wands, 1992) . Since IGF2 exhibits signi®cant cross reactivity with Insulin receptors, it could also act in an autocrine manner through abundant Insulin receptors in the liver. Furthermore, IGF2 interaction with the IGF2/ Mannose-6-phosphate receptor (IGF2/M-6-PR) could aect TGF beta processing and biological activity since those receptors are needed for the reactivation of latent TGFb (Jirtle, 1995) . Irrespective of the mechanism of IGF2 action, the observed 100% reversal of imprinting suggests a strong selection for IGF2 expression during hepatocarcinogenesis.
Materials and methods

Transgenic lines used in the study
Two previously described transgenic lines were utilized in this study. The ®rst line was the IGF2 targeted knockout developed by DeChiara et al. (1990) . Mice that inherit the knocked out IGF2 allele from their sires have an IGF2 null phenotype and are proportional dwarfs, throughout their lives. The second line was a metallothionein 1 regulated TGFa transgenic line developed by Jhappan et al. (1990) . These animals develop intralobular and perilobular ®brosis of the pancreas as well as hepatocellular carcinomas at 12 ± 18 months of age. Crossing hemizygous TGFa dams with IGF2 K/O sires produced F1 hybrids. The animals were genotyped by PCR of tail DNA for the presence of the TGFa transgene and the neomycin insertion of the IGF2 null allele using the following oligos: TGFa: 5'CGTGACTATGCGTGGGCTGGAGCAACC; 3'ACG-ATGGAGACCACCACCAAGGCGGTG; Neomycin: 5' TCGAGCGAGCACGTACTCGGATGGAAG; 3'CTG-C-GAATCGGGAGCGGCGATACC. Tumorigenesis was initiated by maintaining 10-month-old ospring on drinking water containing 25 Mm ZnSO 4 , which induces the metallothionein 1 promoted TGFa transgene 4 ± 6-fold. The animals were sacri®ced at 16 ± 18 months of age. The livers were removed, weighed and sections of normal tissue were either frozen for RNA/protein analysis or ®xed in formalin. All visible liver tumors were dissected and weighed. All tumors under 0.1 g were ®xed in formalin for histological analysis, the remaining tumors were split and either frozen for RNA/protein analysis or ®xed in formalin for histological analysis. Figure 3 (a) Detection of IGF2 mRNA using the semiquantitations RT ± PCR method of (Christofori et al., 1995) . (b) Western blot detection of IGF2, from tumors bearing either two WT IGF2 alleles (TGFa tumor tissue) or one maternal WT IGF2 allele plus one paternal knockout allele (TGFa IGF2 knockout tumor tissue) BMI is a control mRNA from the B 2 Microglobulin gene IFG2 RNA isolation and transcript analysis RNA was extracted from the frozen tissue by a modi®cation of the protocol of Chomczynski and Sacchi (1987) . Fifty mg of tissue was homogenized in 500 ml of homogenization buer (4 M Guanidinium Thiocyanate, 25 mM NaCitrate, 5% Sarcosyl, 100 mM b-mercaptoethanol). Fifty ml of 2 M NaAcetate pH 4.0, 500 ml saturated Phenol and 100 ml of Chloroform was added and the solution was kept on ice for 15 min. After centrifugation at 10 000 g for 20 min the aqueous phase was removed and added to 500 ml of isopropanol, and kept at 7208C for at least 1 h. The precipitate was collected by centrifugation at 10 000 g for 20 min and the pellet was resuspended in 300 ml of homogenization buer and reprecipitated. After two washes with 70% ethyl alcohol the pellet was resuspended in Tris-EDTA.
Reverse transcription PCR was performed using Superscript reverse transcriptase (GIBCO) according to manufacturer's instructions. Five mg of the RNA was added to a tube containing 125 ng random primers (Boehringer), in a total volume of 12 ml. The solution was heated to 708C for 15 min and cooled on ice. Four ml of 56 ®rst strand Buer (GIBCO), 2 ml 1 M DTT and 1 ml of 10 mM dNTP mix was added to the reaction. One ml of reverse transcriptase was added and the solution incubated at 258C for 10 min, then placed at 428C for 1 h. The product was subjected to PCR for 25 cycles with the appropriate IGF2 exon spanning oligos: exon-1:5'GCATAACAGTGGTATCGGCC; 3'-CG-AACAGACAAACTGAAGCG; exon-2: 5'-CGTTCCTCC-TCGCCTCAGAC; 3'-AGGTGTCATATTGGAAGAACT-TGCC; exon-3: 5'CCAGCCTTTTCCTGTCTTCATCC; 3'-AGGTGTCATATTGGAAGAACTTGCC. The products were run on an Ethidium bromide stained agarose gel, and photographed. Semi-quantitative reverse transcription PCR was performed by the method described by Christofori et al. (1995) except that instead of utilizing a-32 P-labeled dATP in the PCR reaction, the PCR reaction was carried out using end labeled 5' oligos. The primers used were b 2 -microglobulin: 5'-GCTATCCAGAAGAAACCCCTCAAATTC; 3'-CA-TGTCTCGATCCCAGTAGACGGTC and IGF2: 5'-CT-TCTACTTCAGCAGGCCTTC; 3'-GTATCTGGGGAAGT-CGTCCGG.
IGF2 protein isolation and analysis
Acid soluble protein was extracted from tumor tissues using a modi®ed version of the method described by Yang and Rogler (1991) . Twenty mg of tissue was homogenized in a solution consisting of 85% ethyl alcohol, 15% HCl, 500 U/ml Aprotinin (Boehringer), 5 mg/ml Leupeptin (Boehringer), 5 mg/ml Pepstatin (Boehringer) and 2 mM Perfbloc (Boehringer). After incubation at 48C overnight, the solution was centrifuged at 13 000 r.p.m. for 15 min and the supernatant lyophilized. The proteins were resuspended in 300 ml of 0.5 M Tris-HCl and subjected to SDS ± PAGE using a 15% gel and transferred at 50 mA, overnight, to a Immobilon-P membrane (Millipore). Western analysis of the immobilized proteins was performed using the ECL system (Amersham). The primary antibody was a rabbit anti rat IGF2 antibody (R&D Antibodies) at a 1 : 1000 dilution.
